| Literature DB >> 30473784 |
Raspail Carrel Founou1,2, Luria Leslie Founou1,3, Sabiha Yusuf Essack1.
Abstract
Background: Gram-negative ESKAPE bacteria are increasingly implicated in several difficult-to-treat infections in developed and developing countries. They are listed by the World Health Organization as resistant bacteria of critical priority in research.Entities:
Keywords: Antibiotic resistance; Carriage; Clonality; ESBLs; ESKAPE bacteria; Hospitalized patients
Mesh:
Substances:
Year: 2018 PMID: 30473784 PMCID: PMC6237030 DOI: 10.1186/s13756-018-0423-0
Source DB: PubMed Journal: Antimicrob Resist Infect Control ISSN: 2047-2994 Impact factor: 4.887
Fecal carriage of resistant Gram-negative ESKAPE bacteria isolated from hospitalized patients in a rural district and a tertiary urban hospital
| Variables | District Rural Hospital | Tertiary Urban Hospital | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Admission, (%) |
| After 48 h, (%) |
| At discharge, (%) | P | Admission, (%) |
| After 48 h, (%) |
| At discharge, (%) |
| |
| Overall | 29.63 | …. | 47.05 | ….. | 50 | …. | 50 | … | 33.33 | … | 66.66 | … |
| Socio-demographic factors | ||||||||||||
|
| ||||||||||||
| Female | 21.4 | 0.333 | 33 | 0.229 | 50 | …. | 40 | 0.590 | 50 | 0.571 | 50 | 0.386 |
| Male | 38.4 | 63 | 0 | 55 | 29 | 100 | ||||||
| Clinical history | ||||||||||||
|
| ||||||||||||
| Yes | 13 | 0.206 | 0 | 0.012 | 0 | 0.248 | 20 | 0.106 | 25 | 0.635 | 100 | 0.386 |
| No | 37 | 67 | 66.67 | 64 | 40 | 50 | ||||||
|
| ||||||||||||
| Yes | 27.78 | 0.766 | 33.33 | 0.402 | 50 | 1.000 | 33 | 0.522 | 33 | 1.000 | 100 | 0.386 |
| No | 33.33 | 54.55 | 50 | 54 | 33 | 50 | ||||||
|
| ||||||||||||
| Yes | 100 | 0.116 | 0 | … | 0 | …. | 75 | 0.046 | 50 | 0.343 | 100 | 0.386 |
| No | 27 | 47 | 50 | 25 | 20 | 50 | ||||||
|
| ||||||||||||
| Medicine | 40 | 0.187 | 56 | 0.457 | 50 | 1.000 | 40 | 0.590 | 40 | 0.635 | 50 | 0.386 |
| Surgery | 17 | 38 | 50 | 55 | 25 | 100 | ||||||
Out of the 45 patients enrolled, some refused rectal sampling, some were discharged or transferred after 48 h, while other could not be sampled due to their condition, leading to variability in number
Risk factors associated with faecal carriage of ESBL-producing Gram-negative ESKAPE bacteria (Univariate Logistic regression)
| Variables | District hospital | Tertiary hospital | ||
|---|---|---|---|---|
| Admission | After 48 h | Admission | After 48 h | |
| OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) | |
| Gender (F or M) | 2.29 (0.42–12.50) | 3.33 (0.45–24.44) | 1.8 (0.21–15.40) | 0.4 (0.16–10.02) |
| Antibiotic use (Yes or No) | 1.3 (0.23–7.32) | 0.42 (0.05–3.31) | 0.43 (0.03–5.98) | 1 |
| Co-morbidity | 1.05 (0.61–1.83) | 1.03 (0.48–2.24) | 1.05 (0.61–1.83) | 1.03 (0.48–2.24) |
| Previous hospitalization | 0.24 (0.02–2.40) | 1 | 0.14 (0.01–1.76) | 0.5 (0.03–8.95) |
| Transferred from another hospital | 1 | 1 | 9 (0.93–86.52) | 4 (0.21–75.67) |
| Ward (Medicine or Surgery) | 0.3 (0.05–1.88) | 0.48 (0.07–3.35) | 1.8 (0.21–15.40) | 0.5 (0.03–8.95) |
Predictive risk factors associated with fecal carriage of MDR Gram-negative ESKAPE bacteria in a district and tertiary hospital (Multivariate Logistic regression)
| Variables | District Hospital | Tertiary Hospital | ||
|---|---|---|---|---|
| Admission; OR (95% CI) | After 48 h; OR (95% CI) | Admission; OR (95% CI) | After 48 h; OR (95% CI) | |
| Gender (F or M) | 7.12 (0.54–93.75) | 3.61 (0.34–37.83) | 1.21 (0.09–15.61) | 0.29 (0.005–16.27) |
| Antibiotic use (Yes or No) | 4.73 (0.28–80.57) | 0.93 (0.08–11.40) | 0.26 (0.007–9.01) | 0.41 (0.009–17.46) |
| Transferred from another hospital | 1 | 1 | 14.40 (0.98–210.84) | 5.72 (0.17–189.00) |
| Hospital Ward (Medicine or Surgery) | 0.08 (0.004–1.39) | 0.42 (0.05–3.81) | 2.09 (0.10–42.29) | 1.14 (0.03–49.14) |
Resistance to selected antibiotics in ESBL-producing Gram-negative ESKAPE bacteria isolated from carriage and clinical samples in a district and tertiary hospital
| Antibiotics | Tertiary hospital | District hospital | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medical ward | Surgical ward | Medical ward | Surgical ward | |||||||||||
| Carriage | Clinical | Carriage | Clinical | Carriage | Clinical | Carriage | ||||||||
| MIC (μg/ml) range | No. resistant isolates (%) | MIC (μg/ml) range | No. resistant isolates (%) | MIC (μg/ml) range | No. resistant isolates (%) | MIC (μg/ml) range | No. resistant isolates (%) | MIC (μg/ml) range | No. resistant isolates (%) | MIC (μg/ml) range | No. resistant isolates (%) | MIC (μg/ml) range | No. resistant isolates (%) | |
| Ampicillin | ≥512 | 4 (100) | ≥32 | 11 (100) | ≥512 | 1 (100) | 16–32 | 8 (100) | ≥512 | 4 (100) | 16- ≥ 32 | 2 (100) | ≥512 | 1 (100) |
| Cefoxitin | 8–512 | 3 (75) | 4 | 7 (64) | 16 | 1 (100) | 8- ≥ 64 | 7 (88) | 128 ≥ 512 | 4 (100) | ≥64 | 2 (100) | ≥512 | 1 (100) |
| Cefuroxime | ≥512 | 4 (100) | ≥64 | 11 (100) | 128 | 1 (100) | 8–64 | 8 (100) | 256 ≥ 512 | 4 (100) | 16- ≥ 64 | 2 (100) | ≥512 | 1 (100) |
| Cefotaxime | ≥512 | 4 (100) | ≥64 | 11 (100) | 128 | 1 (100) | 1- ≥ 64 | 7 (88) | 32- ≥ 512 | 4 (100) | < 1–32 | 2 (100) | ≥512 | 1 (100) |
| Ceftazidime | 512 | 4 (100) | ≥64 | 8 (73) | 256 | 1 (100) | 1- ≥ 64 | 4 (50) | 32- ≥ 512 | 4 (100) | ≤1–16 | 2 (100) | ≥512 | 1 (100) |
| Meropenem | 0.5–2 | 2(50) | 0.25 | 3 (27) | 2 | 1 (100) | 0.25 ≥ 16 | 4 (50) | 0.25–16 | 2 (50) | 0.25 | 0 (0) | 16 | 1 (100) |
| Imipenem | 4–8 | 4 (100) | 0.25 | 3 (27) | 16 | 1 (100) | 0.5- ≥ 16 | 3 (37.3) | 2–32 | 2 (50) | 0.25–1 | 0 (0) | 64 | 1 (100) |
| Ertapenem | 1–2 | 4 (100) | 0.5 | 0 (0) | 16 | 1 (100) | ≤0.5 | 0 (0) | 0.25–8 | 3 (75) | 0.5 | 0 (0) | 64 | 1 (100) |
| Amikacin | 8–128 | 4 (100) | 8 | 2 (18) | 64 | 1 (100) | 2- ≥ 64 | 4 (50) | 8–128 | 2 (100) | 2 | 0 (0) | ≥512 | 1 (100) |
| Gentamicin | 128 | 4 (100) | ≥16 | 8 (73) | 8 | 1 (100) | 1- ≥ 16 | 4 (50) | 4–16 | 4 (100) | 1 | 0 (0) | ≥512 | 1 (100) |
| Ciprofloxacin | 64–512 | 4 (100) | ≥4 | 6 (55) | 32 | 1 (100) | 0.25- ≥ 4 | 5 (45) | 0.5–64 | 3 (75) | ≤0.25 | 0 (0) | 32 | 1 (100) |
| Tigecycline | 16–64 | 4 (100) | 1 | 4 (36) | 16 | 1 (100) | 0.5- ≥ 8 | 3 (37.3) | 2–64 | 4 (100) | 1 | 0 (0) | 8 | 1 (100) |
| Nitrofurantoin | ≥512 | 4 (100) | 128 | 9 (82) | ≥512 | 1 (100) | ≥512 | 6 (55) | ≥512 | 4 (100) | 16- ≥ 512 | 0 (0) | ≥512 | 1 (100) |
| Colistin | 8–512 | 4 (100) | 0.5 | 0 (0) | 8 | 1 (100) | ≤0.5 | 0(0) | 0(0) | 0(0) | ≤0.5 | 0 (0) | ≤0.5 | 0 |
Resistance genes in ESBL-producing Gram-negative ESKAPE bacteria
| Bacteria | No. of strains, | Resistance genes, | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| AmpC | TEM | SHV | CTX-M group-1 | CTX-M group-9 | CTX-M | IMP | VIM | KPC | OXA-1-like | ||
| Tertiary hospital ( | |||||||||||
| | 6 (25) | 2 (33.3) | 4 (66.6) | 4 (66.6) | 3 (50) | 3 (50) | 4 (66.6) | 1 (16.6) | 1 (16.6) | 1 (16.6) | 2 (33.33) |
| | 8 (33.3) | 3 (37.5) | / | 3 (37.5) | 7 (87.5) | 8 (100) | / | / | 4 (50) | 6 (75) | 2 (25) |
| | 7 (29.5) | 1 (14.28) | / | / | 7 (100) | 7 (100) | / | / | / | / | / |
| | 2 (8.33) | 2 (100) | / | 2 (100) | / | 2 (100) | 2 (100) | / | / | / | 2 (100) |
| | 1 (4.16) | / | / | / | 1 (100) | 1 (100) | 1 (100) | 1 (100) | / | 1 (100) | / |
| District hospital (n = 7) | |||||||||||
| | 2 (28.57) | / | 2 (100) | 2 (100) | 1 (50) | 2 (100) | 1 (50) | / | / | / | 2 (33.33) |
| | 1 (14.28) | / | / | / | 1 (100) | 1 (100) | / | / | / | / | / |
| | 2 (28.57) | 1 (50) | 1 (50) | 1 (50) | 1 (50) | 2 (100) | 2 (100) | / | / | / | / |
| | 2 (28.57) | 1 (50) | / | 1 (50) | 1 (50) | 2 (100) | 1 (50) | / | / | / | 1 (50) |
Fig. 1Dendrograms of ESBL-producing of Gram-negative ESKAPE bacteria isolated from carriage and clinical samples from hospitalized patients. a K. pneumoniae, (b) E. aerogenes and cloacae, (c) A. baumannii, (d) P. aeruginosa